We report the development of a systems pharmacology model, based on previously published models of T2DM disease progression and literature-reported results on the impact of IL-1β and IL-1Ra on β-cell mass and function, which accounts for the effect of the inflammatory IL-1 pathway. Here, IL1B is linked to type 2 diabetes mellitus.